Health Care Deal News, June 16, 2014 – Hepatitis C Virus (HCV) is Rocking Pharmaceutical M&A, Interest in Health Care on the Part of Private Equity Firms is at a Fever Pitch, PE Firms are Still Focused on the Services Side of Healthcare

 

Brought to you by www.DealSearchOnline.com
 

June 16, 2014 Issue:
 

Recent Health Care M&A Deals

Behavioral Health Care

 

 

Acquirer

Target

Price

Harbor, Inc.

Behavioral Connections

of Wood County, Inc.

Merger

Biotechnology

 

 

Kite Pharma, Inc.

License for T-Cell Receptor

N/A

Celsion Corporation

EGEN, Inc.

$14 million

NovaDigm Therapeutics

Rights to 3 antigens

N/A

Hospitals

 

 

Stanford Hospital

Valley Care Health System

Merger                              

 

 
Technology Deal of the Week
The hepatitis C virus (HCV) is rocking pharmaceutical M&A, starting last Monday with Merck’s (NYSE: MRK) offer of $3.85 billion for Idenix Pharmaceuticals (NASDAQ: IDIX). The price, representing $24.50 per share, was a 235% premium to IDIX’s prior-day closing price of $7.23. Idenix’s big draw was its three hepatitis C drug candidates, all in clinical development, and the fact that Gilead Sciences (NASDAQ: GILD) got away with pricing its highly successful HCV drug, Sovaldi, at $1,000 per pill. The next day, Achillion Pharmaceuticals (NASDAQ: ACHN) announced that the FDA removed the clinical hold on its experimental HCV treatment, making it the subject of takeover rumors. On Wednesday, OraSure Technologies (NASDAQ: OSUR) maker of point-of-care diagnostics, announced an agreement with AbbVie (NYSE: ABV) to co-promote its OraQuick HCV Rapid Test in the United States, worth up to $75 million in exclusivity payments through 2019. This virus is contagious, for sure. . ……….Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
 
Charted Territory
Interest in health care on the part of private equity firms is at a fever pitch, judging by the number of conferences on the subject. So far this year, PE firms and portfolio companies have spent $7.1 billion in the healthcare space. The momentum isn’t building, however. In Q1:14, we recorded 116 deals announced by private firms, with a total of $4.9 billion in disclosed prices. With about two weeks left to go in Q2:14, just such 75 deals have crossed our radar, with a total of $2.2 billion in disclosed prices. It’s too early to tell if this trend will play out through the rest of the year. Judging by the talk we’ve heard at some of those conferences, though, PE players may start looking elsewhere for better values.
 
Top 5 Health Care Transactions by Private Equity Firms, through June 13 
 

Acquirer

Target

Price

Cinven Capital Management

Medpace, Inc.

$915 million

Clayton, Dubilier & Rice, LLC

Healogics Holding Corp.

$910 million

Montagu Private Equity

Rexam’s healthcare units

$805 million

Sterigenics International, LLC

Nordion Inc.

$758 million

Summit Partners

ABILITY Network

$550 million

Source: The Health Care M&A News, June 2014
Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today
 
Services Deal of the Week
Despite the slowdown in PE investing noted above, PE firms are still focused on the services side of healthcare. Last week Stone Point Capital LLC, through one of its Trident Funds, acquired managed care company LTCG, formerly known as Long Term Care Group. LTCG is the largest provider of comprehensive outsourcing and claims management to long-term care insurers. It administers over 1.4 million policies, representing nearly 20% of all private long-term care insurance……..Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
 
In the Pipeline
Aduro BioTech, Inc., a clinical-stage biotech company based in Berkeley, California, closed a $55 million Series C financing last week, thanks to its biggest benefactor, Johnson & Johnson (NYSE: JNJ). M&A fans will recall the May 29 announcement by JNJ subsidiary Janssen Biotech that it would pay Aduro BioTech $365 million, including upfront license fees, milestones and royalties, for the worldwide license to certain product candidates specifically engineered to treat prostate cancer. The C-round funding included Johnson & Johnson Development Corporation and the Morningside group, as well as new and existing investors……..Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
 
Sponsored Content:
Healthcare Forum 2014, September 17, Boston, MA
Join over 200 senior industry leaders to explore the new disruptions & opportunities altering the health care landscape. Use discount code: EMPMPMAN and save $400. http://econ.st/1pfoKAl 
 
NEW – The Health Care Services Acquisition Report, 20th Edition – Order Today!
Deals have been made. The 2014 Health Care Services Acquisition Report contains private deals in this market that are frequently too small to make it into the financial press. Order by June 30th and get a complimentary $150 of transactions in our online health care M&A database. Now that’s a deal! Go to http://www.levinassociates.com/landing/har20order or call 800-248-1668 to order today.
 
Around the Web in Health Care M&A…Click here to see more
 
Webcast Calendar…Click here to see more
 
Upcoming Conference Partnerships… Click here to see more
 
Previous Issues of Health Care Deal News…Click here to see more